株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

膀胱癌:世界の治験動向

Bladder Cancer Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 212840
出版日 ページ情報 英文 590 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.21円で換算しております。
Back to Top
膀胱癌:世界の治験動向 Bladder Cancer Global Clinical Trials Review, H1, 2017
出版日: 2017年04月30日 ページ情報: 英文 590 Pages
概要

当レポートでは、世界における膀胱癌治療薬の臨床試験のデータを提供し、国別の動向、臨床試験数、有望な治療薬、および主な企業や研究機関別の臨床試験の状況をまとめています。

目次

イントロダクション

  • 膀胱癌
  • レポートガイダンス

臨床試験 地域別

  • 臨床試験 国別
    • 臨床試験に寄与している上位5ヵ国 - アジア太平洋地域
    • 臨床試験に寄与している上位5ヵ国 - 欧州
    • 臨床試験に寄与している上位国 - 北米
    • 臨床試験に寄与している上位国 - 中東およびアフリカ
    • 臨床試験に寄与している上位国 - 中南米

臨床試験:G7 諸国

臨床試験:G7 諸国 治験ステータス別

臨床試験:E7 諸国

臨床試験:E7 諸国 治験ステータス別

臨床試験 相別

  • 進行中の治験 相別

臨床試験 治験ステータス別

未完了の治験

期間ごとの被験者数

有力なスポンサー

主な治験参加企業

有望な治療薬

臨床試験 プロファイル

  • 臨床試験概要: 上位企業
  • 臨床試験概要: トップレベルの大学 / 研究機関 / 病院

5つの主要な臨床試験プロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Bladder Cancer Global Clinical Trials Review, H1, 2017" provides an overview of Bladder Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Bladder Cancer to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Bladder Cancer to Oncology Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 27
  • Subjects Recruited Over a Period of Time 28
  • Clinical Trials by Sponsor Type 29
  • Prominent Sponsors 30
  • Top Companies Participating in Bladder Cancer Therapeutics Clinical Trials 32
  • Prominent Drugs 34
  • Latest Clinical Trials News on Bladder Cancer 35
  • Mar 31, 2017: Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA (pembrolizumab) 35
  • Feb 21, 2017: OncoGenex Pharmaceuticals Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium 35
  • Clinical Trial Profile Snapshots 37

Appendix 586

  • Abbreviations 586
  • Definitions 586
  • Research Methodology 587
  • Secondary Research 587
  • About GlobalData 588
  • Contact Us 588
  • Disclaimer 588
  • Source 589

List of Tables

List of Tables

  • Bladder Cancer Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Bladder Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Bladder Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Bladder Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Bladder Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Bladder Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Bladder Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Bladder Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Bladder Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 20
  • Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Bladder Cancer Therapeutics, Global, Clinical Trials by Phase, 2017* 23
  • Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24
  • Bladder Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
  • Bladder Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Bladder Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Bladder Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
  • Bladder Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
  • Bladder Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
  • Bladder Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

List of Figures

List of Figures

  • Bladder Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Bladder Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Bladder Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Bladder Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Bladder Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Bladder Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Bladder Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Bladder Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Bladder Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 20
  • Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Bladder Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23
  • Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 24
  • Bladder Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Bladder Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Bladder Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Bladder Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
  • Bladder Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
  • Bladder Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
  • Bladder Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34
  • GlobalData Methodology 587
Back to Top